Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease

NCT00252850 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sangamo Therapeutics

Collaborators